Physician profile
Peter J Post
NPI 1336231471
$759.69
in general payments reported to CMS, 2019-2025
20 companies · $39.52 in 2025
The $39.52 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $52.10 · 2022: $237 · 2023: $100 · 2024: $200 · 2025: $39.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $178.24 | 2022-2023 | |
| Novo Nordisk INC | $87.65 | 2019-2024 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.19 | 2022-2024 | Xifaxan, Trulance |
| Amgen INC. | $60.56 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.90 | 2023-2024 | |
| Pfizer INC. | $33.43 | 2022-2023 | |
| Abbott Laboratories | $31.86 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.09 | 2024 | |
| Hologic Sales and Service, LLC | $29.45 | 2019-2024 | Thinprep 2000 Processor, Aptima |
| Insulet Corporation | $24.02 | 2024 | Omnipod |
| Lilly USA, LLC | $20.27 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $19.25 | 2025 | Gardasil 9, Capvaxive, Rotateq |
| Astrazeneca Pharmaceuticals Lp | $17.40 | 2024 | Breztri |
| Sanofi Pasteur INC. | $13.81 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.51 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13.32 | 2019 | |
| Glaxosmithkline, LLC. | $12.56 | 2019 | |
| Allergan, INC. | $12.55 | 2020 | |
| Janssen Pharmaceuticals, INC | $10.96 | 2019 | |
| Sumitomo Pharma America, INC. | $10.67 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Post listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.